Key facts
- Shanghai Best-Link Bioscience’s last known valuation is $138.8M (Dec 2025).
- It has raised $65.7M; the latest was Early Stage VC ($36.7M) in Dec 2025.
- Notable investors include CAS Star, Yonghua Capital, Lapam Capital, Teda VC, Hangzhou Hongcheng Capital — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Shanghai Best-Link Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Shanghai Best-Link Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Shanghai Best-Link Bioscience
Developer of innovative drugs designed for tumor therapy. The company's products are powered by a drug conjugate platform and a precise drug delivery platform based on advanced drug linkage technology, providing customers with precision tumor therapy and tumor immunotherapy.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Website
- bestlinkbio.com/
- Ownership
- Privately Held (backing)
Shanghai Best-Link Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Shanghai Best-Link Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Shanghai Best-Link Bioscience in its N-PORT filings yet. We sweep new filings monthly.